血脂康联合依折麦布对糖尿病前期不稳定性心绞痛患者糖代谢的影响

Effect of Xuezhikang combined with Ezetimibe on glucose metabolism in patients with unstable angina in prediabetes

摘要:

目的观察血脂康联合依折麦布对糖尿病前期不稳定性心绞痛患者的糖代谢影响。方法糖尿病前期不稳定性心绞痛患者210 例。随机分为A 组和B 组，常规治疗基础上，A 组加用阿托伐他汀40 mg；B 组加用血脂康胶囊1.2 g 和依折麦布10 mg 治疗1、6 和12 个月，比较空腹血糖（FBG）、餐后2 h 血糖（2 hPG）、糖化血红蛋白（HbA1c）、新发糖尿病例数变化，以及超敏C 反应蛋白（hs-CRP）、白细胞介素6（IL-6）、肿瘤坏死因子（TNF-α）等。结果①A 组治疗6 和12 个月时的FBG 较基线升高；B 组治疗6 和12 个月时的FBG，1、6和12 个月时的2hPG，12 个月时的HbA1c较基线和与A 组比较，均差异有统计学意义（P <0.05）。②A 组治疗1、6 和12 个月时的hs-CRP，12 个月时的IL-6、TNF-α 较基线下降；B 组治疗1、6 和12 个月时的hs-CRP、TNF-α、6 和12 个月时的IL-6 较基线和与A 组比较，均差异有统计学意义（P <0.05）。结论血脂康联合依折麦布通过抗炎作用改善糖尿病前期不稳定性心绞痛患者糖代谢。

Abstract:

Objective To explore the effect of Xuezhikang (XZK) combined with Ezetimibe on glucose metabolism of patients with unstable angina in prediabetes. Methods A total of 210 unstable angina patients in prediabetes were randomly divided into group A and group B. On the basis of routine treatment, the patients in the group A were given Atorvastatin 40 mg, while those in the group B were given XZK 1.2 g and Ezetimibe 10 mg. All patients were treated for 12 months. Fasting blood glucose (FBG), 2 -hour postprandial blood glucsose (2hPG), glycosylated hemoglobin (HbA1c), the number of patients of newly-diagnosed diabetes, hs-CRP, interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) were examined and compared after 1, 6 and 12 months of medication. Results In the group A, FBG was significantly higher than baseline level after 6 and 12 months of medication (P < 0.05). In the group B, FBG after 6 and 12 months, 2hPG after 1, 6 and 12 months and HbA1c after 12 months were significantly lower than the baseline levels and the levels in the group A (all P < 0.05). In the group A, hs-CRP after 1, 6 and 12 months of medication, and IL-6 and TNF-α after 12 months were significantly lower than the baseline levels (all P< 0.05). In the group B, hs-CRP and TNF-α after 1, 6 and 12 months and IL-6 after 6 and 12 months were significantly lower than the baseline levels and the levels in the group A (all P< 0.05). Conclusions XZK combined with Ezetimibe can improve glucose metabolism of patients with unstable angina in prediabetes maybe through antiinflammation.